Clinical trialsCompany release

Adagene and City of Hope launch Phase 1 trial of ivonescimab plus muzastotug in colorectal cancer

Adagene Inc. (ADAG) · Tue 17 Nov 2026

The investigator-initiated study will enrol up to 36 patients with advanced microsatellite stable metastatic colorectal cancer, testing the combination first alone and then alongside chemotherapy.

Adagene and City of Hope announced on 17 November 2026 that they have started an investigator-initiated Phase 1 trial combining ivonescimab with muzastotug (ADG126) in advanced microsatellite stable metastatic colorectal cancer.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Adagene Inc. ↗

Article written by VigiEye from the official source (Adagene Inc.). Claims are the company's own. AI-assisted; check the source before acting.